scholarly journals Multidetector computed tomography imaging of squamous cell carcinoma of buccal mucosa

2021 ◽  
Vol 7 (10) ◽  
pp. 1683
Author(s):  
Ashwini Sankhe ◽  
Neha Rahatekar ◽  
Diksha Mankar
Keyword(s):  
Computed Tomography ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Multidetector Computed Tomography ◽  
Squamous Cell ◽  
Buccal Mucosa ◽  
Cost Effective ◽  
Imaging Findings ◽  
Proven Case ◽  
Stage Ivb

<p>This study aims at describing the role of multidetector computed tomography (MDCT) and CT imaging findings in evaluation of squamous cell carcinoma of buccal mucosa and its staging. Retrospective study of 40 patients who underwent MDCT and were histopathogically proven case of squamous cell carcinoma (SCC) of buccal mucosa patients were included in the study. Plain, arterial, venous phase and puff cheek CT cuts were taken from base of skull till clavicle. The imaging findings in squamous cell carcinoma (SCC) of the oral cavity allow the radiologist to accurately determine the extent and staging of disease thereby help clinicians plan appropriate treatment. 40 such patients were done in which majority of them are male patients-27 as compared to female patients-13. Among these 40 patients, 20 patients had stage IVB cancer, 13 patients had stage IVA, 5 patients had stage II and 2 patients had stage I cancer. No patient included in our study had stage III.  Patients’ recovery will depend on how early the cancer is found and staging gives an idea of patients’ possible outcomes. MDCT is non-invasive and cost-effective investigation which helps in evaluating squamous cell carcinoma of buccal mucosa and determines its stage of buccal cancer and guide the therapy accordingly.</p>

scholarly journals Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial

BMJ Open ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. e038867 ◽  
Author(s):  
Wenxiu Xin ◽  
Haiying Ding ◽  
Qilu Fang ◽  
Xiaowei Zheng ◽  
Yinghui Tong ◽  
...  
Keyword(s):  
Sensitivity Analysis ◽  
Squamous Cell Carcinoma ◽  
Cost Effectiveness ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Probabilistic Sensitivity Analysis ◽  
Cost Effective ◽  
Platinum Resistant ◽  
The Cost

BackgroundPembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC). However, the cost-effectiveness of pembrolizumab versus chemotherapy in China remains uncertain.ObjectiveThis analysis aimed to describe the cost-effectiveness of pembrolizumab versus standard-of-care (SOC) therapy in r/mHNSCC in China.DesignA Markov model consisting of three health states (stable, progressive and dead) was developed to compare the cost and effectiveness of pembrolizumab with SOC in platinum-resistant r/mHNSCC. Model inputs for transition probabilities and toxicity were collected from the KEYNOTE-040 trial, while health utilities were estimated from a literature review. Cost data were acquired for the payer’s perspective in China. Costs and outcomes were discounted at an annual rate of 3.0%. Sensitivity analyses were conducted to test the uncertainties surrounding model parameters.Outcome measuresThe primary outcome was incremental cost-effectiveness ratios (ICERs), which were calculated as the cost per quality-adjusted life years (QALYs).ResultsThe total mean cost of pembrolizumab and SOC was US$45 861 and US$41 950, respectively. As for effectiveness, pembrolizumab yielded 0.31 QALYs compared with 0.25 QALYs for SOC therapy. The ICER for pembrolizumab versus SOC was US$65 186/QALY, which was higher than the willingness-to-pay threshold (WTP) of US$28 130/QALY in China. The univariate sensitivity analysis indicated that utility values for progressive state, probability from stable to progressive in the SOC group, as well as cost of pembrolizumab were the three most influential variables on ICER. The probabilistic sensitivity analysis demonstrated that standard therapy was more likely to be cost-effective compared with pembrolizumab at a WTP value of US$28 130/QALY. Results were robust across both univariate analysis and probabilistic sensitivity analysis.ConclusionsPembrolizumab is not likely to be a cost-effective strategy compared with SOC therapy in patients with platinum-resistant r/mHNSCC in China.Trial registration numberNCT02252042; Post-results.

Diagnostic Accuracy of Multislice Contrast CT scan in Detection of Squamous cell Carcinoma of Oral cavity, in clinically suspected Patients

2021 ◽  
Vol 15 (8) ◽  
pp. 2500-2501
Author(s):  
Aliya Khan ◽  
Abid Ali Sahito ◽  
Mahreen Shaikh ◽  
Humera Jabeen ◽  
Humaira Ashraf ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Squamous Cell Carcinoma ◽  
Oral Cavity ◽  
Diagnostic Accuracy ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Gold Standard ◽  
Multislice Computed Tomography ◽  
Multislice Ct ◽  
Sensitivity Specificity

Objective: To evaluate the diagnostic accuracy of multislice computed tomography (CT) in detection of squamous cell carcinoma (SCC) of oral cavity in clinically suspected patients taking histopathology as gold standard. Material and Methods: This cross-sectional study has been conducted at Radiology department of Civil Hospital Karachi from 8th September 2018 to March 2019. All the cases having suspected oral squamous cell carcinoma and either of gender were included. Patients underwent computed tomography by using multislice scanner. Then patients undergone biopsy sampling and patients were labeled as positive or negative for squamous cell carcinoma of oral cavity on MDCT and histopathology. Sensitivity, specificity, and diagnostic accuracy of multislice CT for squamous cell carcinoma of oral cavity were measured taking histopathology as gold standard. Results: Total 168 cases were studied and out of them males were 76.8% and females were 23.2%. Mean gutka addiction history was 11.52±5.21 years. Mean lesion size on CT scan was 2.44±1.43 cm. In our study, 35.1% patients were diagnosed positive by multislice computed tomography and 43.5% through histopathology. Sensitivity, Specificity, PPV, NPV and accuracy were 86.4%, 79.8%, 69.9%, 91.6%, and 82.1% respectively. Conclusion: Multislice CT observed to be the effective diagnostic tool for the detection of SCC of oral cavity. Keywords: Multislice Computed Tomography, cancer, Oral Cavity

Sign in / Sign up

Export Citation Format

Share Document